The search had no time limitations and included the following keywords combined in specific strings: TB, LTBI, toxicity, adverse events, safety, tolerability, anti-TB drugs, and preventive therapy.
In the present study, we develop by the first time, a unified multitasking model based on quantitative-structure biological effect relationships (mtk-QSBER) for the simultaneous prediction of anti-TB activity and toxicity against Mus musculus and Rattus norvegicus.
Taken together, long-term therapy with r84 produced no observable toxicity in TB or NTB animals.
Additionally, the existing drugs in the TB regimen are toxic (Fluoroquinolones & Aminoglycosides show hepatotoxicity and renal toxicity, respectively) that deters compliance and leads to poor-treatment outcomes [4, 5].
Regimes for anti-TB therapies are guided by local microbiology advice, based on sensitivities and there is still considerable toxicity from current TB therapy, especially agents used to treat XDR-TB.
The battle against MTB by using antimicrobial chemotherapies will depend on the design of new chemicals with high anti-TB activity and low toxicity as possible.
Variations in efavirenz tolerability during rifampicin treatment may therefore be attributed to pharmacogenetic factors that influence neuropsychiatric toxicity during TB-HIV co-treatment.
In this context a negative IP-10 test may prompt a more vigorous search for other pathologies (e.g. using alternative diagnostic strategies including thoracoscopy), and reduce exposure to unwarranted or empiric anti-TB treatment and its attendant toxicity.
In the management of HIV and tuberculosis (TB) patients, short- and long-term toxicity data play a critical role in informing treatment choices [ 11– 13].
12 The use of isoniazid in low income countries is limited by difficulties of ruling out TB disease before initiation, 13 liver toxicity 14 16 and poor adherence.
No major toxicity related to anti-TB therapy was encountered in our group of patients.
